SCHEMBL6477652

SCHEMBL6477652

COc1cc(C)c(Br)cc1C12CC3CC(CC(C3)C1)C2

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC11 Q96DB2 2/20 0.42
HDAC2 Q92769 1/20 0.42
RARA P10276 3/20 0.41
RARB P10826 3/20 0.41
RARG P13631 3/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
LMNA P02545 2/20 0.41
NR1I2 O75469 1/20 0.41
PGR P06401 1/20 0.41
HSPD1 P10809 1/20 0.41
GOT1 P17174 1/20 0.41
GLRA1 P23415 1/20 0.41
BLM P54132 1/20 0.41
HSPE1 P61604 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
HDAC1 Q13547 1/20 0.40
HDAC7 Q8WUI4 1/20 0.40
HDAC8 Q9BY41 1/20 0.40
HDAC6 Q9UBN7 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6475755 0.79 RARA (0.43) HDAC11HDAC2RARARARBRARG
SCHEMBL9853377 0.78 RARA (0.43) HDAC11HDAC2RARARARBRARG
SCHEMBL9320558 0.78 RARA (0.42) HDAC11HDAC2RARARARBRARG
SCHEMBL1914338 0.78 IKBKB (0.43) HDAC11HDAC2RARARARBRARG
SCHEMBL10014917 0.78 RARA (0.52) HDAC11HDAC2RARARARBRARG
SCHEMBL12309425 0.77 HDAC11 (0.40) HDAC11HDAC2RARARARBRARG
SCHEMBL1914173 0.77 TRPV6 (0.44) MEN1KMT2ALMNATDP1FAAH
SCHEMBL1914211 0.77 RARA (0.42) HDAC11HDAC2RARARARBRARG
SCHEMBL9320668 0.77 RARA (0.55) HDAC11HDAC2RARARARBRARG
SCHEMBL12309928 0.77 PRKDC (0.55) HDAC11HDAC2RARARARBRARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1269788-C Bicyclic aromatic compounds and their use in human or veterinary medicine and in cosmetic processes GALDERMA RES DEV S N C (FR) 2006-08-16 CN disclosed
US-6924388-B2 Bicyclic aromatic compounds and pharmaceutical/cosmetic compositions comprised thereof GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2005-08-02 US disclosed
US-20040092594-A1 Bicyclic aromatic compounds and pharmaceutical/cosmetic compositions comprised thereof GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2004-05-13 US disclosed
US-6632963-B1 Are useful for the treatment of a wide variety of disease states, whether human or veterinary, for example dermatological, rheumatic, respiratory, cardiovascular and ophthalmological disorders, as well as for the treatment of GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) 2003-10-14 US disclosed
EP-0947496-B1 Bicyclic aromatic compounds and their use in human and veterinary medicine as well as in cosmetology GALDERMA RES & DEV (FR) 2002-10-09 EP disclosed
CN-1346828-A Dicyclic aromatic compound and use thereof in human or animal medicine and cosmetic process CT INTERNAT DE RES ES DERMATOL (FR) 2002-05-01 CN disclosed
CN-1241558-A Bicyclic aromatic compounds and their use in human or veterinary medicine and in cosmetic processes GALDERMA RESEARCH DEV S N C (FR) 2000-01-19 CN disclosed
EP-0947496-A1 Bicyclic aromatic compounds and their use in human and veterinary medicine as well as in cosmetology Galderma Research & Development, S.N.C. (FR) 1999-10-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040092594-A1 Bicyclic aromatic compounds and pharmaceutical/cosmetic compositions comprised thereof AHR, TYR, MC1R HDAC11 274/4885HDAC2 138/4885RARA 198/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.